Treating PSMA-positive patients with mHSPC with the radioligand 177Lu-PSMA-617 on top of standard of care reduces their risk for radiographic progression or death. In patients with PSMA-positive ...

Prostate-specific membrane antigen (PSMA)-PET appeared to cut the risk for treatment failure by half in patients receiving salvage radiotherapy (RT) after radical prostatectomy, without increasing ...

PSMA-PET quantification required labor-intensive semiautomated software not in routine use. The study enrolled a high-risk metastatic castration-resistant prostate cancer subgroup, limiting ...

A new study from Denmark shows for the first time that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to ...

Platelet level may indicate response to 177Lu PSMA therapy in radium-223 treated patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu PSMA) appears effective following treatment with radium 223 (223 Ra) ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify ...

Ga-68 PSMA-11 radiotracer may be a feasible option for SCINTIX radiation therapy in patients whose prostate cancer has spread to the bones. Gallium-68 (Ga-68) prostate-specific membrane antigen (PSMA) ...

Among 134 men undergoing radical prostatectomy, PSMA PET accurately identified pathological tumor stage in 45% of patients compared with 28% of patients with MRI (P=0.003), reported Adam Kinnaird, MD, ...

Thomas Hope presents on the combination of pembrolizumab, an immune checkpoint inhibitor, with PSMA-based radioligand therapy for prostate cancer. His presentation highlighted the potential of this ...